Survodutide Phase 3 SYNCHRONIZE-JP trial initiates, assessing 3.6/6.0 mg weekly for Japanese obesity.
Background
Effective pharmacotherapy for obesity disease management in Japan faces an unmet need, with current options often falling short for significant, sustained weight reduction. Survodutide is an investigational glucagon receptor/glucagon-like peptide-1 receptor (GLP-1R) dual agonist, a mechanism hypothesized to induce greater weight reductions than GLP-1R mono-agonists by leveraging both metabolic pathways. This trial addresses the critical gap for Japan-specific efficacy and safety data, crucial for informing clinical practice and regulatory decisions in a population with distinct genetic and lifestyle factors.
Study Design
The SYNCHRONIZE-JP trial is a 76-week, randomised, double-blind, parallel-group, multi-centre, phase 3 clinical trial (NCT06176365). Eligible Japanese adults aged ≥18 years with BMI ≥35 kg/m2 (and ≥1 obesity complication) or BMI ≥27 kg/m2 (and ≥2 obesity complications, with at least one being type 2 diabetes (T2D), hypertension, or dyslipidaemia) were enrolled. Participants were randomised 1:1:1 to receive once-weekly survodutide 3.6 mg, survodutide 6.0 mg, or placebo. All arms included a reduced-calorie diet and increased physical activity. Primary endpoints are percentage change in body weight and achievement of body weight reduction ≥5% from baseline to Week 76.
Results
The SYNCHRONIZE-JP trial enrolled 274 Japanese participants, providing a comprehensive baseline profile for the study population. Of these, 24.1% had type 2 diabetes (T2D), reflecting a significant comorbidity burden. The mean age of participants was 53.1 years, with 47.8% being female. The average baseline BMI was 33.2 kg/m2, indicating a substantial degree of obesity. > The most prevalent obesity complications observed were dyslipidaemia, affecting 81.4% of participants, and hypertension, present in 72.6%. Other notable complications included hyperuricaemia (30.3%) and metabolic dysfunction-associated steatotic liver disease (26.6%). These baseline characteristics confirm a high-risk population, underscoring the unmet need for effective treatments like survodutide in this demographic.
Key Findings
- SYNCHRONIZE-JP is a 76-week Phase 3 RCT evaluating survodutide 3.6 or 6.0 mg weekly for obesity in Japanese adults.
- The trial enrolled 274 Japanese participants with a mean age of 53.1 years and mean BMI of 33.2 kg/m2.
- Baseline data show 24.1% of participants had type 2 diabetes (T2D).
- Dyslipidaemia (81.4%) and hypertension (72.6%) were the most common obesity complications.
- Primary endpoints include percentage body weight change and ≥5% weight reduction from baseline to Week 76.
Why It Matters
This Phase 3 trial is critical for establishing the efficacy and safety of survodutide specifically for Japanese adults with obesity, a population often underrepresented in global trials. The results will provide Japan-specific data, essential for clinical translation and regulatory approval in the region. If positive, survodutide could offer a potent new pharmacotherapy option, potentially surpassing the weight loss achieved by existing GLP-1R mono-agonists due to its dual glucagon receptor/GLP-1R agonism. This could significantly impact treatment protocols, offering clinicians a more effective tool for managing obesity disease and its associated complications like T2D, dyslipidaemia, and hypertension in Japanese patients. The detailed protocol and baseline data lay the groundwork for a robust evaluation of this promising compound.
survodutide
obesity
type-2-diabetes
dyslipidemia
hypertension
phase-3-trial